Center-specific causal inference with multicenter trials: reinterpreting trial evidence in the context of each participating center
多中心试验中的中心特定因果推断AI 解读 ↓
本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。
本页为预印本版本;arXiv 收录、作者填写的期刊信息以及作者既有发表经历,都不单独证明本篇已接收。作者发表记录按 OpenAlex 身份与完整姓名、本站覆盖期刊 ISSN 及正式卷期核对,只展示已核实例,档案仍可能误合并。
引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。
AI 根据所提供的论文材料归类:摘要明确讨论随机试验结果向各中心人群的解释、中心特定处理效应识别与估计,因此归入因果推断。
多中心试验中的中心特定因果推断AI 解读 ↓
正在核对关联版本…
正在核对对应版本的资源…
In multicenter randomized trials, when effect modifiers have a different distribution across centers, comparisons between treatment groups that average over centers may not apply to any of the populations underlying the individual centers. Here, we describe methods for reinterpreting the evidence produced by a multicenter trial in the context of the population underlying each center. We describe how to identify center-specific effects under identifiability conditions that are largely supported by the study design and when associations between center membership and the outcome may be present, given baseline covariates and treatment ("center-outcome associations"). We then consider an additional condition of no center-outcome associations given baseline covariates and treatment. We show that this condition can be assessed using the trial data; when it holds, center-specific treatment effects can be estimated using analyses that completely pool information across centers. We propose methods for estimating center-specific average treatment effects, when center-outcome associations may be present and when they are absent, and describe approaches for assessing whether center-specific treatment effects are homogeneous. We evaluate the performance of the methods in a simulation study and illustrate their implementation using data from the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis trial.